Word

NOVO NORDISK

Status

Registered

Status Code

700

Status Date

Tuesday, April 13, 2021

Serial Number

79290058

Registration Number

6317854

Registration Date

Tuesday, April 13, 2021

Mark Type

3000

Filing Date

Friday, April 3, 2020

Published for Opposition

Tuesday, January 26, 2021

Trademark Owner History

Novo Nordisk A-S - Original Registrant

Classifications

1 Chemical preparations for use in industry; chemical additives for use in the manufacture of pharmaceuticals, cosmetics, hair lotions, disinfectants; chemical diagnostic reagents for industrial use, for non-medical and non-veterinary purposes; chemical preparations for use in the oil industry

5 Pharmaceutical preparations for the treatment of diabetes and obesity; pharmaceutical preparations for haemostasis management and for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease; pharmaceutical preparations for hormone therapy and stem cells for medical purposes; drug delivery devices containing pharmaceutical preparations for haemostasis management, pharmaceutical preparations for the treatment of sickle cell disease, brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, pharmaceutical preparations for hormone therapy and stem cells for medical purposes; chemical preparations for use in medical devices, namely, drug delivery agents consisting of compounds that deliver a wide range of pharmaceuticals

9 downloadable electronic publications, namely, leaflets, books, booklets, handouts, magazines, as well as medical, instructional and teaching material in the field of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable electronic publications featuring electronic reports containing results from clinical trials and studies in the field of prevention and treatment of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable software applications for use with mobile devices for monitoring and management of medical data related to diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; computer hardware and downloadable software, for use with medical injection devices for collecting, transmitting, and displaying medical data; downloadable medical software for the management of medical data related to diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable software as a medical device, namely, software used in connection with medical devices to manage treatment of haemostasis management and for the treatment of sickle cell disease, brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cells for medical purposes

10 Medical and surgical apparatus and instruments, namely, hypodermic syringes and syringe pens; medical apparatus and instruments for reconstitution and injection of pharmaceutical preparations; medical apparatus and instruments, namely, injection devices for administration of pharmaceutical preparations, medical infusion pumps for delivering measured amounts of solutions into the bloodstream over time, infusion pump controllers, adhesive infusion devices for administering drugs; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical and surgical apparatus and instruments, namely, injection devices for the administration of pharmaceutical preparations and the wireless transmission of medical data in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical devices, namely, automatic needle insertion devices, protection caps for hypodermic syringes and medical pens; needles for injections; cartridges and carpules for administration of pharmaceutical preparations

41 Educational services, namely, organizing and conducting educational programmes, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; arranging and conducting of educational conferences, congresses, seminars, symposiums and workshops related to the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment

42 Providing scientific research information in the field of diabetes, obesity, haemostasis management, treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing temporary use of online non-downloadable software featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment

44 Providing medical services via websites and mobile apps for the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing medical information and medical counselling featuring the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment

The color(s) blue is/are claimed as a feature of the mark.
The mark consists of the stylized wording "NOVO NORDISK" below a design of a bull with a circle above its head, all in the color blue.
The English translation of "NOVO NORDISK" in the mark is "NEW NORDIC".

Trademark Events

Aug 15, 2021

Final Decision Transaction Processed By Ib

Jul 27, 2021

Final Disposition Notice Sent To Ib

Jul 27, 2021

Final Disposition Processed

Jul 13, 2021

Final Disposition Notice Created, To Be Sent To Ib

Apr 13, 2021

Registered-Principal Register

Feb 6, 2021

Notification Processed By Ib

Jan 26, 2021

Official Gazette Publication Confirmation E-Mailed

Jan 26, 2021

Published For Opposition

Jan 13, 2021

Notification Of Possible Opposition Sent To Ib

Jan 6, 2021

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jan 6, 2021

Notification Of Notice Of Publication E-Mailed

Dec 17, 2020

Approved For Pub - Principal Register

Dec 17, 2020

Teas/Email Correspondence Entered

Dec 17, 2020

Correspondence Received In Law Office

Dec 17, 2020

Teas/Email Correspondence Entered

Nov 11, 2020

Correspondence Received In Law Office

Dec 17, 2020

Examiner's Amendment Entered

Dec 17, 2020

Notification Of Examiners Amendment E-Mailed

Dec 17, 2020

Examiners Amendment E-Mailed

Dec 17, 2020

Examiners Amendment -Written

Dec 9, 2020

Correction From Ib Entered - Attorney Review Required

Nov 18, 2020

Correction Sent To Ib

Nov 11, 2020

Teas Response To Office Action Received

Oct 10, 2020

Correction Transaction Received From Ib

Sep 27, 2020

Refusal Processed By Ib

Sep 6, 2020

Non-Final Action Mailed - Refusal Sent To Ib

Sep 2, 2020

Refusal Processed By Mpu

Sep 1, 2020

Correction Created For Ib

Jul 30, 2020

Non-Final Action (Ib Refusal) Prepared For Review

Jul 29, 2020

Non-Final Action Written

Jul 28, 2020

Application Filing Receipt Mailed

Jul 24, 2020

Assigned To Examiner

Jul 24, 2020

New Application Office Supplied Data Entered In Tram

Jul 23, 2020

Sn Assigned For Sect 66a Appl From Ib